Rhelion Life Sciences Corp.RHEL.CN
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · CSE · Canada · redlight.co
Legal-psychedelics company selling psilocybin truffles and grow kits in the Netherlands and, via its April 2026 acquisition of Filament Health Corp., developing pharmaceutical-grade natural psilocybin drug candidates led by PEX010. A rename to Rhelion Life Sciences Corp is pending CSE approval.
Key ratios
FCF / Sales
-64.4%TTM
2025
-40.7%2024
-82.5%2023
-163.3%
Net margin
-119.2%TTM
2025
-81.8%2024
-160.5%2023
-136.7%
ROA
-13.6%TTM
2025
-11.6%2024
-14.3%2023
-9.8%
ROE
-31.4%TTM
2025
-22.9%2024
-33.1%2023
-20.9%
Revenue growth
4.1%2025
2024
20.3%2023
69.8%
Recent news
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Southern California for the Expanded Mindfulness Assisted Psychedelic Therapy Trial
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes New Extraction of IBEX011, Its Naturally Derived Ibogaine Drug Candidate, and Commences Stability Testing
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Agreement to Supply PEX010 to Linkoping University for PsiloSAD Trial in Social Anxiety Disorder
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Supply Belgium's First Psilocybin Compassionate Use Program, to Help Open the Door to Patient Access for Treatment-Resistant Depression
Rhelion Life Sciences Reappoints Dr. Robin Carhart-Harris as Scientific Advisor
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Licence Agreement with the University of California, San Francisco for a Phase 2 Trial of Psilocybin in Methamphetamine Use Disorder Among People with HIV
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Calgary for Phase 2 Trial of Psilocybin-Assisted Therapy for PTSD in Survivors of Intimate Partner Violence
Rhelion Life Sciences' Filament Health Issued New Canadian Patent, Extending Psilocybin Patent Estate
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Delivers PEX010 to Bruyère Health Research Institute's Phase 3 Trial of Microdose Psilocybin in Palliative Care
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010
Track RHEL.CN in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer